推荐应用
Purity
Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
SEC-HPLC
The purity of Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) is 99.37%, determined by SEC-HPLC.
FACS
Human CTLA-4 & Human PD-1 CHO-K cells were stained with Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.2270 ug/mL.
Research in vivo
Ipilimumab inhibited the tumor growth of MC38 on huCTLA-4 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 99.3% at 0.88 mpk at D37.
-25~-15℃保存，有效期1年。
【选购指南】类器官研究之构建与起始细胞鉴定抗体推荐
249
2026-07-21
【选购指南】类器官研究之功能成熟度评估抗体推荐
254
2026-07-21
【应用方向】趋化因子信号传导通路——身体“信号导航”解析
262
2026-07-21
【选购指南】重度抑郁症(MDD)通路研究抗体推荐
228
2026-07-21
【选购指南】帕金森病(PD)代谢机制核心抗体研究指南
264
2026-07-21
【应用方向】抗体助力心脏免疫研究——解锁心衰防治新方向
222
2026-07-21
【应用方向】抗体助力心肌肥大与心衰研究：从基础探索到科研应用
234
2026-07-21
【应用方向】抗体助力癌症代谢通路研究——肿瘤代谢科普与研究工具指南
241
2026-07-21
【应用方向】造血干细胞研究相关抗体选型与推荐
18031
2026-04-14
【应用方向】间充质干细胞（MSC）应用研究抗体推荐—用于表型表征、机制研究与分化评估的常用靶标与抗体选型参考
20246
2026-04-14
【应用方向】抗体应用研究—细胞死亡
20252
2026-07-16
【应用方向】Anti-B7-H3/CD276：不只是免疫checkpoint，更是肿瘤进展的“助推器”
18301
2026-02-05
【前沿资讯】上新 | 抗Payload抗体，助力ADC药物动力学分析
19423
2024-07-17
【技术讲解】选对标签抗体，蛋白研究不用愁！
15995
2026-04-14
